Healios KK
4593
Company Profile
Business description
Healios KK is involved in development and sales of opthalmological surgery adjuvants and research, development and manufacture of cell therapy products and regenerative medicine products. The company is developing treatments for age-related macular degeneration and organ anlage transplantation therapy. The company develops next-generation cell therapies using a proprietary gene-edited induced pluripotent stem cell (iPSC) platform, with programs targeting immuno-oncology, ophthalmology, liver diseases, ischemic stroke, and acute respiratory distress syndrome.
Contact
1-1-2 Yurakucho
Hibiya Mitsui Tower 12Floor, Work Styling
Chiyoda-ku
Tokyo100-0006
JPNT: +81 345908006
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
102
Stocks News & Analysis
stocks
SpaceX rally continues, expanding sky-high valuations
SpaceX has risen 50% from its IPO price to become the second-most-expensive stock under Morningstar’s coverage.
stocks
This US AI champion’s stock is too cheap to ignore
Even as competition looks likely to build, the company remains a leading wide-moat business securely at the center of the AI ecosystem.
stocks
Why SpaceX is coming to your Super Fund
Most Australians will end up owning SpaceX — whether they like it or not.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,030.00 | 43.20 | -0.48% |
| CAC 40 | 8,467.98 | 37.19 | 0.44% |
| DAX 40 | 25,026.80 | 92.13 | 0.37% |
| Dow JONES (US) | 51,564.70 | 72.15 | 0.14% |
| FTSE 100 | 10,399.70 | 108.91 | -1.04% |
| HKSE | 23,924.81 | 387.35 | -1.59% |
| NASDAQ | 26,517.93 | 496.28 | 1.91% |
| Nikkei 225 | 71,109.13 | 55.64 | 0.08% |
| NZX 50 Index | 13,433.08 | 69.77 | 0.52% |
| S&P 500 | 7,500.58 | 80.48 | 1.08% |
| S&P/ASX 200 | 8,814.20 | 42.40 | -0.48% |
| SSE Composite Index | 4,090.48 | 17.59 | -0.43% |